Redeye is positive to the news that EMA has returned with positive feedback to IRLAB’s phase III pla...
Redeye states that the Q4 report came in above our estimates on both sales and EBITDA, and Sivers re...
Redeye’s initial comments on the Q4 report from Waystream.
Redeye’s comments on Xbrane following its year-end report, which showed negative revenue growth both...
Redeye provides its initial take on Navigo’s Q4 2024 report, which beat our sales estimate but misse...
Q4: +4% org. sales growth, 39% adj. EBITA growth, strong cash flow '25e-'26e adj.
Redeye’s first comments on the Q4 report this morning.
Minor estimate revisions due to M&A contribution Utilisation trend is positive '25e EV/EBITA of 8x, ...
Redeye comments on Teneo AI’s Q4, aligning strong preliminary figures showing a rapid acceleration i...
Nanexa’s Q4 report did not reveal much new, although the conference call provided welcome clarity on...
Redeye updates its view on Nanologica following the year-end report and recent news flow.
Redeye updates on Raketech following the company’s Q4 report where we have lowered our growth foreca...
Net sales were EUR ~104m and EBITDA came in at EUR ~2m in Q4 2024, according to preliminary informat...
Redeye updates its estimates following Surgical Science’s Q4 2024 report.
Redeye updates its estimates and valuation after OEM’s Q4 2024 report.
Solid Q4 in light of headwinds, FX revaluations boost margin We push 5% EE growth from '25e to 26e, ...
We cut underlying '25e-'26e EBITA by 5-4%, mainly in service units Positioned to accelerate M&A in m...
Redeye provides its initial take on OEM’s Q4 2024 report, which came in above our estimates.
Redeye comments on Integrum’s directed share issue and we adjust our fair value range per the new nu...
Redeye comments on Avensia’s Q4 report, showing solid growth and cash flow but an adjusted EBIT some...
